Table 1.
US FDA-Approved BCR-ABL1 TKIs
| Name | Year approved | Indications in CML |
|---|---|---|
| Imatinib |
2001 |
CP, AP, or BC after failure of interferon therapy |
| 2003 |
Newly diagnosed CP |
|
| Dasatinib |
2006 |
CP, AP, or BC after resistance to or intolerance of imatinib |
| 2010 |
Newly diagnosed CP |
|
| Nilotinib |
2007 |
CP or AP after resistance to or intolerance of imatinib |
| 2010 |
Newly diagnosed CP |
|
| Bosutinib |
2012 |
CP, AP, or BC after resistance to or intolerance of prior therapy |
| Ponatinib | 2012 | CP, AP, or BC after resistance to or intolerance of prior TKI therapy |
AP accelerated phase, BC blast crisis, CML chronic myelogenous leukemia, CP chronic phase, FDA Food and Drug Administration, TKI tyrosine kinase inhibitor, US United States.